Taysha Gene Therapies Inc... (TSHA)
NASDAQ: TSHA
· Real-Time Price · USD
5.34
0.18 (3.59%)
At close: Oct 15, 2025, 3:59 PM
5.33
-0.19%
After-hours: Oct 15, 2025, 07:27 PM EDT
3.59% (1D)
| Bid | 5.16 |
| Market Cap | 1.27B |
| Revenue (ttm) | 8.1M |
| Net Income (ttm) | -92.72M |
| EPS (ttm) | -0.34 |
| PE Ratio (ttm) | -15.71 |
| Forward PE | -11.74 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 5.47 |
| Volume | 4,162,496 |
| Avg. Volume (20D) | 5,820,400 |
| Open | 5.34 |
| Previous Close | 5.16 |
| Day's Range | 5.21 - 5.51 |
| 52-Week Range | 1.05 - 5.51 |
| Beta | 0.97 |
| Ex-Dividend Date | n/a |
About TSHA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TSHA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TSHA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsTaysha Gene Therapies Inc. is scheduled to release its earnings on
Nov 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+53.46%
Taysha Gene Therapies are trading higher after the...
Unlock content with
Pro Subscription
4 months ago
+12.7%
Taysha Gene Therapies shares are trading higher after the company provided details regarding the trial design for TSHA-102 and clinical data from part A of its REVELA Phase 1/2 trials. Additionally, the company announced a $200 million public offering and Chardan Capital raised its price target on the stock from $7 to $9.
2 months ago · seekingalpha.com
Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call TranscriptTaysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Hayleigh Collins - Director of Corporate Communications & Investor Relations...
